典型文献
Conventional treatments and non-PEGylated liposome encapsulated doxorubicin for visceral leishmaniasis: A scoping review
文献摘要：
Visceral leishmaniasis (VL), also known as Kala-azar, is caused by Leishmania (L.) donovani complex, which includes L. donovani and L. infantum and is associated with a high death rate as compared to the cutaneous and subcutaneous form. Treatment of VL includes chemotherapeutic agents which are associated with some major hurdles like toxicities, parenteral administration, high cost, parasite resistance and stability. Hence, there is an urgent requirement to develop novel chemotherapeutic agents or repurposing of existing drugs against VL. Developing formulation of new chemical entity for the treatment of VL is laborious, time consuming and associated with huge financial burden. However, screening of existing chemotherapeutic agents is a good alternative to avail cost-effective treatment option for VL. Non-PEGylated liposome encapsulated doxorubicin (Myocet?) is proposed as an alternative treatment option for VL in this review article. Here, we covered the fundamental aspects of VL, loophole associated with available current treatment strategies and non-PEGylated liposome encapsulated doxorubicin as a novel alternative formulation for treating VL, as this liposomal delivery system of doxorubicin might passively target the intra-cellular regions of macrophage.
文献关键词：
中图分类号：
作者姓名：
Soumya Ranjan Satapathy;Rudra Narayan Sahoo
作者机构：
School of Pharmaceutical Sciences,Siksha'O'Anusandhan(Deemed to be University),Bhubaneswar,India
文献出处：
引用格式：
[1]Soumya Ranjan Satapathy;Rudra Narayan Sahoo-.Conventional treatments and non-PEGylated liposome encapsulated doxorubicin for visceral leishmaniasis: A scoping review)[J].亚太热带医药杂志（英文版）,2022(07):293-307
A类：
Kala,azar,Myocet,loophole
B类：
Conventional,treatments,PEGylated,liposome,encapsulated,doxorubicin,visceral,leishmaniasis,scoping,review,Visceral,VL,also,known,caused,by,Leishmania,donovani,complex,which,includes,infantum,associated,high,death,compared,subcutaneous,Treatment,chemotherapeutic,agents,major,hurdles,like,toxicities,parenteral,administration,cost,parasite,resistance,stability,Hence,there,urgent,requirement,develop,novel,repurposing,existing,drugs,against,Developing,formulation,new,chemical,entity,laborious,consuming,huge,financial,burden,However,screening,good,alternative,effective,option,Non,proposed,this,article,Here,covered,fundamental,aspects,available,current,strategies,treating,liposomal,delivery,system,might,passively,target,intra,cellular,regions,macrophage
AB值：
0.52505
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
